Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 34 recruiting now early-phase tilt

Crohn Disease: early-phase trial registry

34 of 72 indexed Crohn Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #191 of 28,707 conditions by registered trial count.

72 US clinical trials · 34 currently recruiting · #191 of 28,707 conditions by registered trial count

Crohn Disease: 72 US clinical trials tracked, 34 recruiting.

Crohn Disease is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 34 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 6 of these trials.

Enrollment posture brief

Registry condition crohn-disease

OPEN 34 | RECR 47% | LATE 13 | EARLY 20 | RANK #191 | SPON 6

Nearest open-share peer: Psychosis (47% recruiting · 36 trials)

NSCLC66.7%Crohn Disease (this)47%Chronic Low Back Pain41.7%Hodgkin Lymphoma38.9%HIV-1-infection33.3%
Open-enrollment share among volume-matched conditions near Crohn Disease

Crohn Disease lists 34 open slots (47% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Crohn Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Crohn Disease is recruiting above its size-band peers.

    34 of 72 indexed trials (47.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Crohn Disease trials is spread across many organizations.

    Massachusetts General Hospital accounts for 6 of 72 trials (8.3%). 51 distinct sponsors appear on at least one study for this condition label.

  3. Typical Crohn Disease enrolment sits around 84 participants.

    Median target enrolment is 84 among the 72 trials that report a genuine target (sentinel values excluded). 38 of those (52.8%) plan for fewer than 100 participants.

  4. Crohn Disease research is mostly interventional.

    58 interventional and 14 observational studies make up this index (80.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 111Phase 29Phase 35Phase 48

Open and recent trials

72 total, page 2 of 2

COMPLETED Phase 3 386 participants

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Janssen Scientific Affairs

NCT03464136

COMPLETED Phase 2 290 participants

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Teva Branded Pharmaceutical Products R&D

NCT05499130

COMPLETED NA 187 participants

Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.

Medtronic - MITG

NCT03241368

COMPLETED Phase 3 147 participants

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Boehringer Ingelheim

NCT02871635

COMPLETED Phase 4 102 participants

Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)

Cedars-Sinai Medical Center

NCT03723447

COMPLETED NA 84 participants

Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System

Capso Vision

NCT04573959

COMPLETED NA 69 participants

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

Cedars-Sinai Medical Center

NCT00829595

COMPLETED Phase 1 64 participants

A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease

Celgene

NCT02367183

COMPLETED Phase 4 55 participants

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Takeda

NCT02764762

COMPLETED NA 55 participants

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

University of Washington

NCT05651542

COMPLETED Phase 2 55 participants

A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

NCT05013905

COMPLETED NA 45 participants

SMART-IBD App Trial

Children's Hospital Medical Center, Cincinnati

NCT06023667

COMPLETED NA 30 participants

Transcutaneous VNS to Treat Pediatric IBD

Northwell Health

NCT03863704

COMPLETED NA 30 participants

Digital Behavioral Interventions in Inflammatory Bowel Disease

Montefiore Medical Center

NCT04861597

COMPLETED Early Phase 1 22 participants

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

MediBeacon

NCT03962998

COMPLETED Phase 4 21 participants

Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas

Vanderbilt University Medical Center

NCT00517296

COMPLETED NA 21 participants

Effect of Grapes in Inflammatory Bowel Disease

Case Western Reserve University

NCT05972694

COMPLETED NA 20 participants

Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease

Texas A&M University

NCT02227602

COMPLETED Phase 1 15 participants

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

Stacy A. Kahn

NCT02330653

COMPLETED NA 11 participants

Analysis of Biologic Signatures in Crohn's Patients Undergoing Surgery

Weill Medical College of Cornell University

NCT06146335

COMPLETED Phase 1 9 participants

FMT in Pediatric Crohn's Disease

Children's Hospital Los Angeles

NCT03194529

COMPLETED Phase 4 4 participants

Flagyl Microbiome in Crohn's Disease

University of Louisville

NCT04682522

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 11
Phase 2 9
Phase 3 5
Phase 4 8

Named interventions

Most-linked intervention names on Crohn Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Ustekinumab Drug
4 trials
Placebo Other
3 trials
Infliximab Drug
2 trials
Placebo Biological
2 trials
Blood Draw Diagnostic test
2 trials
Cyclophosphamide Drug
2 trials
Side-to-side anastomosis (SSa) Procedure
1 trials

US sites by state

Facility locations filed on Crohn Disease trials. A trial with sites in several states counts in each.

California 22 trials
New York 17 trials
Ohio 15 trials
Massachusetts 15 trials
Florida 15 trials
Georgia 11 trials
Connecticut 10 trials
Texas 9 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Crohn Disease page

72 registered trials, 34 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Crohn Disease condition card totals 72 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.